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Abstract
Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the 
phosphatidyl-inositol 3-kinase (PI3K)–Akt pathway are common and therapeutically targeted in 
triple-negative breast cancer (TNBC). However, activation of another EGFR family member 
[human epidermal growth factor receptor 3 (HER3) (or ErbB3)] may limit the antitumor effects of 
these drugs. We found that TNBC cell lines cultured with the EGFR or HER3 ligand EGF or 
heregulin, respectively, and treated with either an Akt inhibitor (GDC-0068) or a PI3K inhibitor 
(GDC-0941) had increased abundance and phosphorylation of HER3. The phosphorylation of 
HER3 and EGFR in response to these treatments was reduced by the addition of a dual EGFR and 
HER3 inhibitor (MEHD7945A). MEHD7945A also decreased the phosphorylation (and 
activation) of EGFR and HER3 and the phosphorylation of downstream targets that occurred in 
response to the combination of EGFR ligands and PI3K-Akt pathway inhibitors. In culture, 
inhibition of the PI3K-Akt pathway combined with either MEHD7945A or knockdown of HER3 
decreased cell proliferation compared with inhibition of the PI3K-Akt pathway alone. Combining 
either GDC-0068 or GDC-0941 with MEHD7945A inhibited the growth of xenografts derived 
from TNBC cell lines or from TNBC patient tumors, and this combination treatment was also 
more effective than combining either GDC-0068 or GDC-0941 with cetuximab, an EGFR-targeted 
antibody. After therapy with EGFR-targeted antibodies, some patients had residual tumors with 
increased HER3 abundance and EGFR/HER3 dimerization (an activating interaction). Thus, we 
propose that concomitant blockade of EGFR, HER3, and the PI3K-Akt pathway in TNBC should 
be investigated in the clinical setting.
Introduction
Triple-negative breast cancer (TNBC) is clinically defined by the absence of estrogen 
receptor (ER), progesterone receptor, and human epidermal growth factor receptor (EGFR) 
2 (HER2) overexpression or amplification. It represents 15 to 20% of newly diagnosed 
breast cancer, affects women in the reproductive age, and often follows an aggressive 
clinical course, with early recurrences in the form of distant visceral metastases, including to 
the brain (1–3). On the other hand, this tumor type has been demonstrated to be more 
responsive to cytotoxic therapy than ER-positive breast cancers (4-6). The current 
neoadjuvant strategies for TNBC use taxane/ anthracycline-based regimens, which 
reportedly achieve “pathological complete response” (pCR; defined as no invasive and no in 
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situ residual tumors in breast and nodes) in about 20% of patients in unselected cohorts (7). 
TNBC has been described as having a high frequency of inactivation or decreased 
expression of the gene encoding phosphatase and tensin homolog deleted on chromosome 
10 (PTEN) (1, 8), as well as overexpression of the gene encoding human EGFR in up to 
about 50% of cases (9, 10). These biochemical features offer the opportunity to explore 
novel potential therapeutic strategies in this breast cancer subtype. Clinical benefits from the 
EGFR inhibitor cetuximab (11, 12) and the pan–phosphatidylinositol 3-kinase (PI3K) 
inhibitor NVP-BKM120 (13) have been reported in TNBC patients. However, none of these 
studies showed durable responses.
Preclinical evidence suggests that inhibition of the PI3K-Akt-mTOR (mammalian target of 
rapamycin) axis induces compensatory genetic expression and activation of upstream 
receptor tyrosine kinases (RTKs), including EGFR and, most prominently, HER3 (also 
known as ErbB3) (14–17). This may reduce the antitumor effects of single-agent PI3K 
pathway blockade. Furthermore, studies using cellular models of cetuximab resistance 
suggest that HER3 itself can limit the sensitivity to cetuximab by increasing EGFR-HER3 
heterodimerization and activation of downstream pathways (18). Although HER3 targeting 
is being explored in other breast cancer subtypes (19, 20), no rationale has yet been provided 
for the inhibition of this RTK in TNBC. Here, we hypothesized that targeting both EGFR 
and HER3 in combination with inhibition of the PI3K-Akt pathway would enhance the 
therapeutic response in EGFR-positive TNBC.
Results
Blockade of EGFR and HER3 combined with inhibition of the PI3K-Akt pathway results in 
superior antitumor activity
HCC70 and MDA-MB-468 TNBC cell lines, characterized by increased abundance of 
EGFR and loss of PTEN expression (fig. S1), were treated with GDC-0068 [a selective 
inhibitor of the Akt1, 2, and 3 isoforms (21)], GDC-0941 [a class I selective pan-PI3K 
inhibitor (22)], MEHD7945A [an antibody targeting both EGFR and HER3 (23)], or a 
combination of these inhibitors in the presence of either EGF or heregulin (NRG1), ligands 
for EGFR and HER3, respectively. Consistent with other reports (14–16), treatment with 
either GDC-0068 or GDC-0941 increased the abundance of HER3 and, in HCC70 cells, 
induced the phosphorylation (activation) of both EGFR and HER3 (Fig. 1A). The addition 
of MEHD7945A prevented the EGF-or NRG1-induced activation of EGFR and HER3 and 
reduced the phosphorylation of the downstream mTOR effector ribosomal protein S6 and 
extracellular signal–regulated kinase (ERK) pathways in both cell lines (Fig. 1A). The 
effects of MEHD7945A on the phosphorylation of ERK in cells triggered by EGF are mild, 
likely because of the high abundance of EGFR in these cells. Notably, GDC-0068 competes 
for the adenosine 5′-triphosphate (ATP)–binding site of Akt and is known to cause increased 
phosphorylation of the enzyme at its two regulatory sites [Thr308 and Ser473 (21)], as is 
evident in the blots.
Given its effects on Akt and ERK activation, we tested whether combining MEHD7945A 
with either GDC-0068 or GDC-0941 would enhance the antiproliferative response in 
HCC70 and MDA-MB-468 cells. In cells treated with single or double agents for 5 days, we 
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observed varying sensitivity to the single agents GDC-0068 and GDC-0941, but in every 
case, the combination of the PI3K- or Akt-targeted agents and MEHD7945A considerably 
inhibited cell proliferation more effectively than did either single agent (Fig. 1B).
To expand our findings in vivo, we first tested the efficacy of MEHD7945A in combination 
with either GDC-0068 or GDC-0941 in both HCC70- and MDA-MB-468–derived 
xenografts (fig. S2). Whereas both types of tumors responded only modestly to any of the 
single agents (GDC-0068, GDC-0941, or MEHD7945A), the combination of GDC-0068 or 
GDC-0941 and MEHD7945A yielded significantly superior tumor growth inhibition 
compared to monotherapy. Moreover, one-third of the animals in the cohorts of both 
combination regimens achieved complete tumor shrinkage, with no relapses observed 90 
days after treatment cessation. We next investigated the abundance and activation of EGFR 
and HER3 in HCC70-derived xenografts collected at the end of each experiment. The 
technical challenge of obtaining reliable detection of phosphorylated HER3 by 
immunohistochemistry (IHC) and the small amount of tissue available from the tumors 
treated with the combination regimens prompted us to assess these using an alternative 
methodology. Frozen tissue was analyzed by collaborative enzyme enhanced reactive-
immunoassay (CEER), a platform that uses reversed-phase detection of nanogram quantities 
of protein (22). Treatment with GDC-0068 or GDC-0941 increased the abundance and 
phosphorylation of both EGFR and HER3 (fig. S3 and table S1A). The increased 
phosphorylation of EGFR after GDC-0068 treatment was most likely a result of increased 
EGFR/HER3 heterodimerization because we observed no changes in the total abundance of 
EGFR. As expected, the cotreatment of MEH-D7945A prevented receptor phosphorylation 
induced by either GDC-0068 or GDC-0941.
To test the response to these treatments in patient-derived xenografts (PDXs) of TNBC, we 
used available patient tumors in our laboratory. These tumors were characterized by IHC to 
have undetectable abundance of PTEN, high abundance of EGFR, and generally high (more 
than 50%) staining for the proliferation marker Ki67 (fig. S4). These features predicted a 
particularly aggressive phenotype, confirmed by the rapid growth of the tumor xenografts in 
untreated mice (Fig. 1C). Single-agent treatment with GDC-0068, GDC-0941, or 
MEHD7945A delayed tumor growth, whereas the combination of either GDC drug with 
MEHD7945A caused durable tumor stasis (Fig. 1C). Consistent with the cell line–derived 
xenografts, the abundance of HER3 and EGFR increased after inhibition of the PI3K-Akt 
pathway. The addition of MEH-D7945A effectively prevented HER3 phosphorylation and 
kept that of EGFR at the same abundance as in control tumors (Fig. 1D and table S1B). The 
capability of Akt inhibitors to increase the abundance of EGFR and HER3 in PDXs was also 
confirmed by positron emission tomography (PET). From the PET scans, we found a visibly 
higher accumulation of 89Zr-MEHD7945A in the tumor of the GDC-0068–treated cohort of 
mice compared to the control group (fig. S5). Quantification of the uptake of 89Zr-
MEHD7945A in GDC-0068–treated or untreated tumors revealed a nearly twofold higher 
tracer (89Zr) accumulation in the treated group compared to control mice. Liver 
accumulation of 89Zr-MEHD7945A is considered as the main route of excretion of the 
probe.
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Tumor cell proliferation was also measured using the Ki67 index in specimens from 
xenografts collected at the experimental endpoints. We found that the percentage of Ki67-
positive cells was significantly lower only in the combination therapy cohorts (fig. S6A). 
These results were further confirmed measuring the number of Ki67-positive circulating 
tumor cells (CTCs) in mice bearing PDXs greater than 1 cm3 in volume and treated for 6 
days with GDC-0068, GDC-0941, MEH-D7945A, or the combination of these agents (fig. 
S6B). Collectively, these data show that targeting both EGFR and HER3 enhanced the 
antitumor effects of PI3K-Akt inhibitors.
HER3 suppression improves the antitumor activity of PI3K-Akt inhibition
To dissect the role of HER3 inhibition in these models, we compared the activity of 
cetuximab (an antibody targeting exclusively EGFR) with MEHD7945A, each in 
combination with either GDC-0068 or GDC-0941 in HCC70 cells. Both cetuximab and 
MEHD7945A enhanced the antiproliferative activity mediated by PI3K-Akt pathway 
inhibition in cells stimulated with EGF; however, MEHD7945A was more effective than 
cetuximab in cooperating with GDC-0068 and GDC-0941 in cells stimulated with NRG1 
(Fig. 2A). The importance of specifically blocking HER3 in this setting was confirmed by 
testing the activity of PI3K-Akt inhibitors after HER3 knockdown by small interfering RNA 
(siRNA). HER3 depletion sensitized MDA-MB-468 cells to the antiproliferative activity of 
either GDC-0068 or GDC-0941 (fig. S7).
We next compared the antitumor effect of combining cetuximab versus MEHD7945A with 
GDC-0941 in HCC70-derived xenografts. Whereas the combination of cetuximab and 
GDC-0941 did not further inhibit tumor growth compared to either single-agent treatment, 
the combination of MEHD7945A and GDC-0941 (concomitantly targeting EGFR, HER3, 
and PI3K) was superior to either cetuximab alone or cetuximab in combination with 
GDC-0941 (Fig. 2B), with no palpable tumor present in four of nine cases. The combination 
of GDC-0068 with cetuximab (tested in both HCC70 and PDX models) appeared to inhibit 
tumor growth in some cases compared to either single agent, but the effect was not 
statistically significant (fig. S8), suggesting that adding cetuximab had no benefit over either 
PI3K-Akt pathway inhibitor alone. Biochemically, both MEHD7945A and cetuximab 
combination treatments with GDC-0941 decreased the phosphorylation of EGFR in HCC70 
xenografts, but only the MEHD7945A combination decreased HER3 activation, although 
this was not statistically significant (Fig. 2C and table S1C). These results suggest that 
HER3 plays an important role in limiting the efficacy of PI3K-Akt pathway inhibitors in this 
model.
Decreased EGFR and increased HER3 abundance are associated with lower response to 
EGFR antagonists in TNBC patients
To investigate whether changes in EGFR and HER3 abundance can affect the response to 
anti-EGFR therapy in TNBC patients, we evaluated the abundance of these receptors in 
samples from patients enrolled in two pilot neoadjuvant clinical trials testing the antitumor 
activity of the EGFR antibodies panitumumab (47 patients) and cetuximab (29 patients) in 
combination with various standard chemotherapies. Of the 47 TNBC patients enrolled in the 
study that combined panitumumab with four standard cytotoxic agents (DNA-damaging 
Tao et al. Page 5






















agents 5-fluorouracil, epirubicin, or cyclophosphamide, or the mitotic inhibitor docetaxel), 
22 patients (46.8%) achieved pCR at the time of surgery (24 weeks after treatment 
commenced), whereas 25 patients (53.2%) showed residual disease (NCT00933517). This 
was a twofold increase in pCR compared to TNBC patients treated only with cytotoxic-
based neoadjuvant chemotherapy (6), which underscores the benefit of adding EGFR-
targeted agents in this setting. Of 29 patients enrolled in the study testing the antitumor 
activity of cetuximab combined with docetaxel, 8 experienced pCR (27.5%) 
(NCT00600249).
IHC assessment of EGFR and HER3 abundance was possible on pre-treatment samples from 
16 patients who achieved pCR with panitumumab combination therapy at time of surgery 
and 24 patients who did not (table S2). We observed a trend toward a higher probability to 
achieve pCR after panitumumab treatment in patients with a pretreatment EGFR score 
higher than 70 (Fig. 3A). No statistical correlation was found between the pre-treatment 
HER3 score and the likelihood to achieve pCR in this cohort. For the cetuximab-treated 
patients, the analysis of EGFR and HER3 abundance before and after treatment was possible 
only for six of the eight patients who reached pCR; thus, because of the low sample size, we 
did not perform the pCR correlation analysis for the patients enrolled in the cetuximab trial. 
The results from the panitumumab trial at least suggest that high EGFR abundance before 
treatment predicts an optimal response to EGFR-targeted antibodies. However, a substantial 
portion (42%) of patients who had high EGFR abundance in the pretreated tumor did not 
show complete response; therefore, we investigated whether changes in the abundance or 
activity of EGFR and HER3 occurred after treatment. For patients who did not achieve pCR 
at the time of surgery, IHC assessment was possible on 24 and 22 paired samples for EGFR 
and HER3, respectively, from the panitumumab trial, and on 19 and 20 paired samples, 
respectively, from the cetuximab trial (table S2). When we considered only the tumors with 
a pretreatment EGFR score higher than 150 (12 from the panitumumab trial and 7 from the 
cetuximab trial), we found decreased EGFR abundance in residual tumors after treatment in 
12 of 19 cases compared with that in the paired pretreatment specimens (Fig. 3, B and C). 
On a side note, we observed a similar trend in a different cohort of samples obtained from 
metastatic TNBC patients enrolled in the TBCRC 001 clinical trial (12), who were treated 
with cetuximab in combination with carboplatin. pCR could not be used as a parameter of 
response given the metastatic nature and the low response rate observed in the study, so we 
examined overall survival. On the basis of gene expression data from 16 paired biopsies 
(before and after 1 to 2 weeks of treatment), we observed decreased overall survival in 
patients with decreased EGFR mRNA in the posttreatment specimens (fig. S9).
The abundance of HER3 in the 22 residual (posttreatment) tumors from panitumumab-
treated patients compared with their pretreatment counterparts was increased in 12 patients 
(Fig. 4, A and B). A similar trend was observed in cetuximab-treated patients: HER3 
abundance was increased in the residual tumors of 13 of 20 available non-pCR patient 
samples compared with that in paired pretreatment specimens (fig. S10). When the data 
from both the panitumumab- and the cetuximab-treated patient samples were pooled, the 
increase in HER3 abundance was statistically significant (table S2). Using fluorescence 
resonance energy transfer (FRET) to analyze EGFR-HER3 dimerization (a mechanism of 
activation), we investigated whether there was increased activation in addition to increased 
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abundance of HER3 in the residual tumors of patients not achieving pCR from EGFR-
targeted therapy. Enough tissue was available in a small cohort of specimens, three patients 
treated with cetuximab and four patients treated with panitumumab. Five of seven of the 
pooled cases displayed increased dimerization of HER3 and EGFR (Fig. 4, C and D). 
Together, these results suggest that increased HER3 expression and HER3 activation may 
mediate residual tumor growth after EGFR-targeted therapy.
Discussion
Here, we found that HER3 may play a critical role in limiting the antitumor effect of 
inhibitors targeting either the PI3K-Akt or EGFR pathway. We demonstrated that 
simultaneously targeting EGFR and HER3 by MEHD7945A enhanced the efficacy of PI3K-
Akt pathway inhibitors in preclinical models of EGFR-positive TNBC. Furthermore, our 
clinical analysis suggests that HER3 abundance and activation are induced in TNBC patients 
by EGFR-targeted therapies and that this change may prevent therapy-induced tumor 
regression. In a study testing the clinical activity of cetuximab in TNBC, only a minority of 
patients whose tumors showed EGFR pathway inhibition derived clinical benefit from the 
therapy, suggesting that different mechanisms of receptor activation may occur in this 
subtype of breast cancer (12). Preclinically, low abundance of EGFR and high abundance of 
HER3, among others, may determine cetuximab resistance in PDX models (24). Moreover, 
HER3 abundance and phosphorylation (a marker of activation) are induced after Akt 
suppression. The first evidence of this feedback activation was reported by pioneering work 
from Sergina et al., who also postulated that HER3 plays a pivotal role in limiting the 
efficacy of HER kinase inhibitors (17). These results were extensively validated using other 
HER inhibitors (25) or specific molecules directly targeting PI3K or Akt (14, 16). We have 
previously shown that this phenomenon also occurs in patients treated with the Akt inhibitor 
GDC-0068 (26). Therefore, our rationale behind simultaneously targeting EGFR, HER3, 
and PI3K in TNBC is derived from the observations that nearly half of TNBC have a high 
abundance of EGFR, that TNBC often has a low abundance of the endogenous Akt inhibitor 
PTEN, and that increased abundance and activation of HER3 appear to limit the sensitivity 
of TNBC to targeted therapy. It is plausible that lower doses of PI3K-Akt pathway inhibitors 
are required to achieve pathway suppression (and, consequently, tumor growth inhibition) 
when both EGFR and HER3 are inhibited. In addition, tumor cells that have a relatively high 
abundance of these receptors can function as molecular “flags” for immune-mediated 
antibody-dependent cytotoxicity, intrinsic characteristics of immunoglobulin G type I 
antibodies such as MEHD7945A in vivo. Thus, the antibody-mediated immune response 
may also explain, at least in part, the higher response to the drug combinations in nude mice 
compared to the in vitro setting.
In conclusion, we believe that simultaneous inhibition of EGFR, HER3, and the PI3K-Akt 
pathway has the potential to greatly expand the percentage of TNBC patients who can 
benefit from targeted therapy. Given that both pharmacokinetic and pharmacodynamic data 
for MEHD7945A, GDC-0068, and GDC-0941 are already available, the design of phase 2 
clinical trials testing the activity of these possible combinations in TNBC would be 
straightforward. Patients may be enrolled on the basis of EGFR abundance in the tumors, 
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and HER3 abundance and activation after PI3K pathway inhibition may be measured with 
either biopsies collected during treatment or live imaging techniques.
Materials and Methods
Study design
The objective of our study was to test the activity of concomitant blockade of EGFR, HER3, 
and the PI3K-Akt pathway in preclinical models of TNBC. Moreover, we aimed to evaluate 
whether the expression of both EGFR and HER3 was influencing the clinical response to 
anti-EGFR therapy in TNBC patients. We planned to treat with GDC-0068 (Akt inhibitor), 
GDC-0941 (PI3K inhibitor), and MEHD7945A (antibody binding to both EGFR and 
HER34) TNBC cell lines and tumors to test the antitumor activity of these compounds 
separately and in combination. Moreover, we planned to test by IHC the expression of both 
EGFR and HER3 in TNBC patients who underwent cetuximab (antibody anti-EGFR)–based 
therapy.
In vitro experiments were performed at least two times and at least in triplicate for each 
replica.
Cell lines and chemical compounds
MDA-MB-468 and HCC70 were purchased from the American Type Culture Collection and 
maintained at 37°C in Dulbecco's modified Eagle's medium/Ham's F-12 1:1 and RPMI 
1640, respectively, with 10% fetal calf serum, L-glutamine (2 mM), penicillin (20 U/ml), and 
streptomycin (20 μg/ml) in a humidified atmosphere and 5% CO2. The pan-PI3K inhibitor 
GDC-0941 was obtained from the Stand Up To Cancer/PI3K Dream Team Mouse 
Pharmacy. The Akt inhibitor GDC-0068 and the dual EGFR-HER3 inhibitor MEHD7945A 
were provided by Genentech. All compounds were dissolved in dimethyl sulfoxide for in 
vitro experiments.
Cell viability and proliferation
For proliferation, 5 × 103 to 8 × 103 cells were seeded in 96-well plates and treated with the 
indicated concentrations of GDC-0068, GDC-0941, and/or MEHD7945A. After 5 days, 
cells were fixed and stained with crystal violet. Cell proliferation was also analyzed with 
CellTiter-Glo Luminescent Cell Viability Assay (Promega) as described by the 
manufacturer. For proliferation in response to heregulin (NRG1; PeproTech) and EGF 
(PeproTech), 5 × 104 cells were treated with GDC-0068, GDC-0941, and/or MEHD7945A 
in the presence of NRG1 (4 ng/ml) or EGF for 5 days and then stained with crystal violet. 
For siRNA experiments, 5 × 103 cells were seeded in 96-well plates and transfected with 
siRNA (Silencer, Ambion) control or a pool of two hairpins targeting human HER3 mRNA 
using DharmaFECT transfection reagent (Thermo Scientific).
Western blotting
Cells were washed with ice-cold phosphate-buffered saline (PBS) and scraped into ice-cold 
radioimmunoprecipitation assay lysis buffer (Cell Signaling Technology) supplemented with 
phosphatase inhibitor cocktails (Complete Mini and PhosphoStop, Roche). Lysates were 
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cleared by centrifugation at 13,000 rpm for 10 min at 4°C, and supernatants were removed 
and assayed for protein concentration using the Pierce BCA Protein Assay Kit (Thermo 
Scientific). Thirty-five micrograms of total lysate was resolved on NuPAGE 4 to 12% bis-
tris gels (Life Technologies) and electrophoretically transferred to Immobilon transfer 
membranes (Millipore). Membranes were blocked for 1 hour in 5% nonfat dry milk in tris-
buffered saline (TBS)–Tween and then hybridized using the following primary antibodies in 
5% bovine serum albumin (BSA) TBS-Tween: phospho-Akt (Ser473), phospho-Akt 
(Thr308), Akt, phospho-S6 (Ser 240/4), phospho-S6 (Ser 235/6), S6, phospho-ERK 
(Thr202/Tyr204), ERK, phospho-EGFR (Tyr1068), EGFR, phospho-HER3 (Tyr1289), and 
HER3 (1:500 to 1:1000; Cell Signaling Technology). b-Actin was used as a loading control 
(1:5000; Sigma), also in 5% BSA TBS-Tween. Mouse and rabbit horseradish peroxidase 
(HRP)–conjugated secondary antibodies (1:50,000; Amersham Biosciences) were diluted in 
2% nonfat dry milk in TBS-Tween. Protein-antibody complexes were detected by 
chemiluminescence with SuperSignal West Femto Chemiluminescent Substrate (Thermo 
Scientific), and images were captured with a G:BOX camera system.
Establishment of tumor xenografts and in vivo treatments
All mouse studies were conducted through Institutional Animal Care and Use Committee–
approved animal protocols in accordance with institutional guidelines. Six-week-old female 
athymic nude mice were purchased from Charles River Laboratories and housed in air-
filtered laminar flow cabinets with a 12-hour light cycle and food and water ad libitum. The 
size of the animal groups was calculated to measure means difference between placebo and 
treatment groups of 25% with a power of 80% and a P value of 0.01. Host mice carrying 
xenografts were randomly and equally assigned to either control or treatment groups. 
Animal experiments were conducted in a controlled and nonblinded manner. For cell line–
derived xenograft studies, mice were injected subcutaneously with 1 × 107 HCC70 or MDA-
MB-468 suspended in 150 μl of culture medium/Matrigel (BD Biosciences) in a 4:1 ratio. 
17β-Estradiol (1 μM) was supplemented in the mouse drinking water as described (27).
For PDX studies, tumors were subcutaneously implanted in 6-week-old female athymic 
nude mice. Upon xenograft growth, tumor tissue was reimplanted into recipient mice, which 
were randomized upon implant growth. For the collection of CTCs, tumors were implanted 
into the mammary pad of athymic nude mice.
Once tumors reached an average volume of ∼150 to 250 mm3, mice were randomized into 
treatment arms, with 7 to 11 tumors per group. GDC-0068 (40 mg/kg) or GDC-0941 (75 
mg/kg) was dissolved in 0.5% methylcellulose and 0.2% Tween-80 (MCT) solution and 
administered once daily via oral gavage. MEHD7945A (10 mg/kg) and cetuximab (10 
mg/kg) were diluted in PBS and injected intraperitoneally twice weekly. Tumors were 
measured by digital caliper over the entire treatment period and harvested 2 hours after the 
last administration of the drug. Tumor volume was determined using the following formula: 
(length × width2) × (π/6). Tumor volumes are plotted as means ± SEM.
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Preparation of 89Zr-MEHD7945A: The MEHD7945A monoclonal antibody (mAb) was 
functionalized with p-isothiocyanatobenzyl-desferrioxamine (DFO-Bz-NCS, Macrocyclics 
Inc.) with a 1:7 mAb/DFO-Bz-NCS ratio. The reaction was incubated at 37°C for 1 hour. 
The modified antibodies were purified using a 10-kD centrifugal filter (GE Vivaspin 
500). 89Zr was produced through proton beam bombardment of yttrium foil and isolated in 
high purity as 89Zr-oxalate at Memorial Sloan Kettering Cancer Center according to 
previously established procedure (28). Labeling of the MEHD7945A-DFO conjugate 
proceeded as described (29) with an obtained specific activity of 2.5 to 3 mCi/mg and >95% 
purities. PET imaging: Scans were recorded with a microPET Focus 120 (Concorde 
Microsystems). Mice (n = 3 for each group, bearing two tumors on each flank) were 
administered with 89Zr-MEH-D7945A (150 to 200 μCi, 50 to 68 μg) in 100 μl of 0.9% 
saline formulations via lateral tail vein injections. Whole-body acquisitions were acquired 
on mice while anesthetized with 1.5 to 2.0% isoflurane (Baxter Healthcare) in oxygen at 24 
to 120 hours after injection. Images were reconstructed via filtered back projection. The 
images were analyzed using ASIPro VM software (Concorde Microsystems). Volumes of 
interest (VOIs) were measured on various planar sections of the acquired image by manually 
drawing on the tumor site. The average VOI was calculated and expressed as percent 
injected dose per gram of tumor tissue (%ID/g). Data values were expressed as means ± SD 
unless otherwise stated. Statistical analysis was performed with GraphPad Prism version 
6.02 software using Student's t test. A P value of <0.05 is considered statistically significant.
Collaborative enzyme enhanced reactive-immunoassay
The abundance and phosphorylation of EGFR and HER3 in xenografts were determined by 
CEER (30, 31). CEER uses the formation of unique immunocomplexes between capture 
antibodies printed on a nitrocellulose microarray surface, with which the target molecule in 
cell lysates reacts, and two independent detector antibodies. One detector antibody is 
conjugated to glucose oxidase, and the other is conjugated to HRP. Target detection 
[expressed as computational unit (CU)] requires the presence of both detector antibodies, 
and the enzyme channeling event between glucose oxidase and HRP will not occur unless 
both antibodies are in close proximity. For each assay, a standard curve was generated from 
eight concentrations of serially diluted reference lysates from cell lines, well characterized 
for the abundance and phosphorylation of RTKs. Each assay included controls along with 
sample lysates. When control lysates provided acceptable values, signals generated from 
samples were quantified against the standard curve. One computational unit for EGFR 
represented about 106 molecules, whereas 1 CU for HER3 represented about 5 × 104 
molecules. Raw data were normalized by the total amount of cytokeratins (CKs) to include 
only protein expressed in the epithelial compartment (table S1).
Circulating tumor cells
CTCs were captured on the herringbone chip, fixed, and permeabilized as previously 
described (32). For capture, the herringbone chip was coated with antibodies against 
EpCAM (epithelial cell adhesion molecule) (R&D Systems) and EGFR (cetuximab; Eli 
Lilly) (33). The CTC-containing chip was incubated with primary antibodies against wide-
Tao et al. Page 10






















spectrum CKs (Abcam), CD45 (Santa Cruz Biotechnology), and Ki67 (Life Technologies), 
and secondary antibodies were conjugated with Alexa Fluor 647, Alexa Fluor 555, and 
Alexa Fluor 488 (all from Life Technologies). Nuclei were stained with 4′,6′-diamidino-2-
phenylindole (DAPI). We used an automated fluorescence microscopy scanning system 
(BioView) to identify Ki67-positive CTCs (CK+/CD45-/Ki67+), Ki67-negative CTCs (CK+/
CD45−/Ki67), and contaminating white blood cells (CD45+).
Immunohistochemistry
For IHC on xenografts, dissected tissues were fixed immediately after removal in a 10% 
buffered formalin solution for a maximum of 24 hours at room temperature before being 
dehydrated and paraffin-embedded under vacuum conditions. Samples were blocked with 
normal goat serum and incubated with Ki67 (Life Technologies), EGFR (Cell Signaling 
Technology), and PTEN (Cell Signaling Technology) antibodies. The antigen-antibody 
reaction was revealed by SignalStain Boost IHC Detection Reagent (8114, Cell Signaling 
Technology) with 3,3′-diaminobenzidine (DAB) as a substrate (Dako). For IHC on patient 
samples, tumor tissue was fixed in 10% buffered formalin for 48 hours and embedded in 
paraffin. Four-micrometer sections were deparaffinized in xylene and hydrated in graded 
alcohols. For EGFR detection, the antigen was retrieved by protease treatment (8 min at 
37°C), and the sections were further incubated at 37°C for 1 hour with a prediluted ready-to-
use mouse mAb to EGFR (clone 3C6, Ventana). The antigen-antibody reaction was 
visualized by ultraView DAB reveal system in a BenchMark XT automated IHC stainer (all 
from Ventana). For HER3, the antigen retrieval was performed by heating the sections at 
97°C for 20 min in EnVision Target Retrieval Solution, High pH (Dako) in PT Link 
apparatus (Dako). The tissues were then incubated at 37°C for 2 hours with a mouse mAb to 
HER3 (clone DAK-H3-IC, Dako) diluted 1:50. The antigen-antibody reaction was revealed 
using EnVision FLEX DAB system in a Dako Autostainer Plus automate. For each patient, 
the pre- and posttreatment tumor samples were run together. IHC staining was interpreted by 
an expert pathologist who was blind to patient information. Both EGFR and HER3 
abundances were quantified using an arbitrary scale having 0, 0.5, 1, 1.5, 2, 2.5, and 3 as 
measures of increasing staining intensity. EGFR and HER3 histoscores were defined as a 
sum of products obtained by multiplying the staining intensity with the percentage of stained 
cells.
Patient samples
For PDX establishment, fresh tissue was obtained from the Massachusetts General Hospital 
under Institutional Review Board approval and patient's informed consent. Triple-negative 
status was determined by the Massachusetts General Hospital Clinical Laboratory and 
Department of Pathology. Formalin-fixed paraffin-embedded (FFPE) specimens for IHC 
analyses of EGFR and HER3 abundance were obtained from the institutions participating in 
two French multicenter pilot phase 2 neoadjuvant trials that tested the efficacy of an anti-
EGFR antibody combined to chemotherapy in TNBC stage II to IIIA patients 
(NCT00933517 and NCT00600249). pCR was the primary endpoint (with clinical response 
and toxicity as secondary endpoints), for which 47 and 29 patients were evaluated in the 
panitumumab and cetuximab trials, respectively (table S2). Tumor tissue samples were 
systematically collected before and at the end of the neoadjuvant treatment at the Jean Perrin 
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Comprehensive Cancer Center, where molecular and pathological analyses were performed. 
pCR was evaluated using Chevallier et al.'s (34) and Sataloff et al.'s (35) classifications.
Fluorescence resonance energy transfer
To monitor FRET between EGFR and HER3, we used fluorescence lifetime imaging 
microscopy (FLIM), which is a gold standard technique for measuring protein proximity 
within the typically less than 10-nm range (36–38), and which we pioneered in its 
application to FFPE cancer samples (39, 40). Two consecutive slices were placed on the 
same glass slide, and antigen retrieval was performed with the Ventana BenchMark ULTRA 
system according to the manufacturer's instructions. One slice was stained for EGFR alone 
[detected by an Alexa Fluor 546-conjugated mAb to EGFR (F4), from the Cancer Research 
UK (CRUK) repository], and the second slice for EGFR and HER3 [detected by a Cy5-
conjugated mAb to HER3 (2F12), Thermo Scientific]. Antibodies were directly labeled 
according to the manufacturer's protocol with Alexa Fluor 546 and Cy5, respectively Both 
antibodies were shown to be specific in either cells overexpressing untagged EGFR (plasmid 
provided by A. Reynolds, Tumor Angiogenesis Group, The Breakthrough Breast Cancer 
Research Centre, London) or enhanced green fluorescent protein-tagged HER3 (a gift from 
S. Roberts, Gray Cancer Institute, Mount Vernon Hospital), or in FFPE sections (fig. S11). 
Samples were imaged on an “open” microscope automated FLIM system (41). Image 
analysis was done using newly developed algorithm to create the lifetime filter to eliminate 
auto-fluorescence, so any lifetime reduction on the masked tumor image will indicate true 
FRET (42).
Statistical analysis
Two- way t tests were performed with GraphPad Prism (GraphPad Software). Error bars 
represent the SEM, and P values are indicated by *P < 0.05 and **P < 0.01. All cellular 
experiments were repeated at least three times. All the in vivo experiments were run with at 
least seven mice for each treatment arm. Statistical analysis on data related to the French 
clinical trial samples was performed with Microsoft Excel and Statistics Epidemiology 
Medicine, a biomedical statistical analysis software created by Kwiatkowski et al. (43).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Therapeutic activity of combined inhibition of EGFR, HER3, and the PI3K-Akt pathway 
in TNBC preclinical models
(A) Western blot for total and phosphorylated EGFR, HER3, and downstream proteins 
HCC70 and MDA-MB-468 (MDA468) cells after the indicated treatments for 24 hours: 
EGF or NRG1, 4 ng/ml; MEHD7945A, 10 nM; GDC-0068 and GDC-0941, 1 μM. (B) 
Analysis of the proliferation of HCC70 (left) and MDA-MB-468 cells (right) treated for 5 
days as indicated; concentrations as in (A). (C) Tumor growth curves of TNBC PDX treated 
as indicated: MEHD7945A (MEHD), 10 mg/kg twice weekly; GDC-0941, 75 mg/kg daily; 
GDC-0068, 40 mg/kg daily. (D) CEER analysis of total and phosphorylated EGFR and 
HER3 in PDXs treated as indicated. Blots in (A) are representative of and data in (B) are 
means ± SEM from two experiments. n ≥ 8 and n ≥ 3 for each treatment arms in (B) and 
(D), respectively; *P = 0.048 in (C), GDC-0941 + MEHD versus GDC-0941, and *P = 
0.007, GDC-0068 + MEHD versus GDC-0068. (D) **P = 0.054, GDC-0941 + MEHD 
versus GDC-0941, two-sided Student's t test.
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Fig. 2. Efficacy of MEHD7945A or cetuximab in combination with PI3K inhibition
(A) Left: Proliferation analysis of HCC70 cells treated for 5 days as indicated in the 
presence of EGF (top) or NRG1 (bottom). MEHD7945A (MEHD) and cetuximab (Cetux), 
10 nM; GDC-0068 and GDC-0941, 1 μM. Right: Western blot for phosphorylated and total 
EGFR and HER3 in HCC70 cells treated as indicated. Blots are representative of two 
experiments. (B) Tumor growth curves of HCC70 xenografts treated as indicated, doses as 
in Fig. 1A. (C) CEER analysis of active and total EGFR and HER3 in HCC70 xenografts 
treated as indicated. Data are means ± SEM. n≥8 and n≥3 for each treatment arms in (B) and 
(D), respectively, at least three tumors per condition; (B) *P = 0.020, GDC-0941 + MEHD 
versus GDC-0941, and P= 0.0054, GDC-0941 + MEHD versus GDC-0941 + Cetux. (C) 
**P = 0.0004, GDC-0941 + MEHD versus control, and P < 0.0001, GDC-0941 + Cetux 
versus control. (C) ***P = 0.054, GDC-0941 + MEHD versus GDC-0941, Student's t test.
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Fig. 3. EGFR expression and response to anti-EGFR therapy in TNBC patients
(A) Correlation between the abundance of EGFR (table S2) and pCR in 47 TNBC patients 
treated with panitumumab combination therapy (receiver operating characteristic curve, P = 
0.08). (B) EGFR abundance in tumors before and after treatment with either panitumumab 
or cetuximab combination therapy in patients who did not achieve pCR (P = 0.0048). (C) 
Representative IHC images (×25 magnification) of EGFR abundance in residual tumors 
(posttreatment) versus baseline specimens (pre-treatment). Scale bars, 80 μm.
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Fig. 4. HER3 expression and response to anti-EGFR therapy in TNBC patients
(A) HER3 abundance by IHC in tumors before and after panitumumab-based treatment in 
patients who did not achieve pCR (P = 0.0028). (B) Representative IHC (×25 magnification) 
from two patient tumors analyzed in (A). Scale bars, 80 μm. (C) FRET analysis of HER3-
EGFR dimerization in residual tumors from a subset of patients who did not achieve pCR 
after treatment with panitumumab/cetuximab-based therapy. (D) Representative time-
resolved immunofluorescence images (×20 magnification) from two tumors analyzed in (A) 
to (C). Grayscale image shows intensity of the donor fluorophore, and pseudocolor image 
shows the pixel-by-pixel FRET efficiency values. Scale bar, 50 μm.
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